{"id":"W2242669247","doi":"10.1200/jco.2012.30.15_suppl.3572","title":"Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, <i>k-RAS</i> wild-type (WT), metastatic colorectal carcinoma (mCRC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne; University of Toronto; Moncton Hospital; Ottawa Hospital; Princess Margaret Cancer Centre; Niagara Health System; Hôpital de l'Enfant-Jésus","funders":"","keywords":"Medicine; Cetuximab; Bevacizumab; Internal medicine; Clinical endpoint; Oncology; Placebo; Randomized controlled trial; Phases of clinical research; Colorectal cancer; Clinical trial; Cancer; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002047494,0.001044946,0.001211289,0.000387324,0.0002895959,0.0009180991,0.0005688781,0.00144702,0.002754705],"category_scores_gemma":[0.002422629,0.0003652874,0.001126414,0.0005373319,0.0005168868,0.0004038943,0.0002407386,0.00281589,0.0003753833],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001068109,"about_ca_system_score_gemma":0.001777334,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001422485,"about_ca_topic_score_gemma":0.003978487,"domain_scores_codex":[0.9994294,0.0003333182,0.00002721474,0.00006841499,0.00008050584,0.00006108054],"domain_scores_gemma":[0.998415,0.0005053757,0.0004425283,0.00005098625,0.0001484568,0.0004376833],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8869453,0.004226582,0.01996696,0.001145547,0.002617075,0.0002797614,0.00008873479,0.0008383013,0.01612002,0.0001818639,0.01430489,0.05328498],"study_design_scores_gemma":[0.6969569,0.1948042,0.08651629,0.0001945115,0.004491201,0.0007151199,0.00005422757,0.001977822,0.005847771,0.0001976683,0.008158215,0.00008600319],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9695236,0.0168573,0.0004419007,0.004178995,0.0007614156,0.002246828,0.002555773,0.000104072,0.003330064],"genre_scores_gemma":[0.9854869,0.00334091,0.001281103,0.002255214,0.0005895055,0.001514559,0.003355775,0.00002816547,0.002147824],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002754705,"threshold_uncertainty_score":0.01082832,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04399735343700889,"score_gpt":0.3877906369926702,"score_spread":0.3437932835556613,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}